Announcements Trials
Browse Landscape

Phase

Phase 2 62Phase 1 41Phase 3 10Phase 1/2 9Phase EARLY_PHASE1 3Phase 4 3Phase 2/3 3Phase NA 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1

Conditions

Melanoma 2Skin Neoplasms 1Neoplasms 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Vemurafenib × Clear all
NCT01683188 2021-02-01

PROCLIVITY01

Clinigen, Inc.

Phase 4 Terminated
53 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01739764 2021-01-07

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Hoffmann-La Roche

Phase 4 Completed
215 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT01898585 2020-01-07

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 4 Completed
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡